Novartis: Cosentyx helps relieve axial SpA patients
(CercleFinance.com) - Data showed that psoriasis drug Cosentyx helped patients realize early and lasting relief in axial spondyloarthritis, Novartis said on Thursday.
Full 52-week results from a Phase III trial showed reinforced benefits of Cosentyx across the axial spondyloarthritis (axial SpA) spectrum, the Swiss drugmaker said.
The study found patients treated with Cosentyx showed significant and sustained improvements in signs and symptoms of non-radiographic axial spondyloarthritis at 52 weeks, it said.
Axial SpA is an inflammatory disease characterised by chronic inflammatory back pain affecting 1.7 million people in the five largest EU countries and the US.
Copyright (c) 2020 CercleFinance.com. All rights reserved.